Potential disease-modifying therapy enters Phase 2
"Following the review of the data of the 101 trial, the drug advanced to the Phase II 201 trial (NCT05424276). This is a 12-week, randomized, double-blind,...
"Following the review of the data of the 101 trial, the drug advanced to the Pha...